1,366 reports of this reaction
10.1% of all EPTINEZUMAB JJMR reports
#2 most reported adverse reaction
MIGRAINE is the #2 most commonly reported adverse reaction for EPTINEZUMAB JJMR, manufactured by Lundbeck Pharmaceuticals LLC. There are 1,366 FDA adverse event reports linking EPTINEZUMAB JJMR to MIGRAINE. This represents approximately 10.1% of all 13,519 adverse event reports for this drug.
Patients taking EPTINEZUMAB JJMR who experience migraine should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MIGRAINE is a frequently reported adverse event for EPTINEZUMAB JJMR, accounting for a significant proportion of all reports.
In addition to migraine, the following adverse reactions have been reported for EPTINEZUMAB JJMR:
The following drugs have also been linked to migraine in FDA adverse event reports:
MIGRAINE has been reported as an adverse event in 1,366 FDA reports for EPTINEZUMAB JJMR. This does not prove causation, but indicates an association observed in post-market surveillance data.
MIGRAINE accounts for approximately 10.1% of all adverse event reports for EPTINEZUMAB JJMR, making it one of the most commonly reported side effect.
If you experience migraine while taking EPTINEZUMAB JJMR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.